“Nothing changes if nothing changes.”
Why an integrated commercialization platform with the amplified power of a direct-to-patient (DTP) channel is no longer an option. It’s a must.
Two-thirds of drug launches fall short of revenue goals, but a new approach is changing the trend. Today’s most successful brands are rethinking the traditional playbook by pairing integrated commercialization models with direct-to-patient (DTP) channels that expand market reach, accelerate access, and improve adherence.
This article spotlights the measurable impact of EVERSANA COMPLETE Commercialization® and EVERSANA DIRECT Commercialization™, including proven revenue gains, significant cost savings, and patient access improvements. From increasing onboarding and refill rates to cutting acquisition costs nearly in half, the evidence shows how these innovative approaches transform both new launches and mature brands.
By integrating DTP with a unified commercialization partner, brand teams can break down silos, align financial incentives and scale patient engagement like never before.
Early adopters, based on data provided by EVERSANA DIRECT Commercialization™, have realized tangible improvement in several key metrics, reporting these improvements:
- Onboarding/conversion rates (whereby prescriptions written by HCPs are dispensed and received by the patient) up to 95%, versus the 50% industry average
- Adherence/refill rates of 90% versus 50% industry average
- Patient-acquisition costs that are 30 to 50% lower than previously possible
READ OUR IMPACT ACTIVATION STORY
Download the full article to see how leading life sciences companies are using these models to boost peak revenue forecasts by billions, cut field force costs and create a more equitable path to therapy access.
IMPACT ACTIVATION STORY
A brand team projected a U.S. market of 6 million patients for a new therapy. By adding a DTP channel to its commercialization strategy, they have an opportunity to reach 16 million more diagnosed-but-untreated patients, plus undiagnosed and potentially eligible.
With digital outreach and AI insights, peak revenue forecasts jumped by $1B.
The gain came from:
- 12M additional prescriptions from diagnosed-but-untreated patients
- 9M from newly identified undiagnosed patients
- 33% boost in adherence through targeted digital support.
Critically, the DTP approach enabled the company to cut its planned field force in half— shrinking from 600 reps at launch to 300 over a decade. That reduction translates to $200M in savings, helping offset commercialization costs while sustaining growth.
Author
As President of EVERSANA, Gregory is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of executive leadership, Gregory understands all facets of…
Penny’s extensive background and expertise in finance, corporate development, business development, marketing, and experience with startups informs the work she does helping life science companies optimize support services and distribution models to commercialize new…